肝细胞癌(HCC)是其发病的主要原因之一。慢性肝病患者的死亡率和医疗支出。印度尚无关于HCC诊断和管理的共识指南。印度全国肝脏研究协会（INASL）于2011年成立了HCC工作组，其任务是制定HCC诊断和管理的共识指南。与印度的疾病模式和临床实践有关。工作队首先确定了HCC各个方面的各种有争议的问题，这些问题被分配给工作队的个别成员，他们对这些问题进行了详细的审查。工作组使用牛津循证医学中心-2009年的证据水平来开发基于证据的方法。2月9日和10日举行了为期2天的圆桌讨论会,2013年在普里，奥里萨邦,讨论,辩论,并最终确定共识声明。工作队成员在本次会议上审查并讨论了现有文献，并为每个问题制定了INASL共识声明。我们在这里介绍INASL关于预防的共识指南(Puri建议)，印度肝癌的诊断和治疗。
Hepatocellular carcinoma (HCC) is one of the major causes of morbidity, mortality and healthcare expenditure in patients with chronic liver disease. There are no
consensus guidelines on diagnosis and management of HCC in India. The Indian National Association for Study of the Liver (INASL) set up a Task-Force on HCC in 2011, with a mandate to develop
consensus guidelines for diagnosis and management of HCC, relevant to disease patterns and clinical practices in India. The Task-Force first identified various contentious issues on various aspects of HCC and these issues were allotted to individual members of the Task-Force who reviewed them in detail. The Task-Force used the Oxford Center for Evidence Based Medicine-Levels of Evidence of 2009 for developing an evidence-based approach. A 2-day round table discussion was held on 9th and 10th February, 2013 at Puri, Odisha, to discuss, debate, and finalize the consensus statements. The members of the Task-Force reviewed and discussed the existing literature at this meeting and formulated the INASL
consensus statements for each of the issues. We present here the INASL
consensus guidelines (The Puri Recommendations) on prevention, diagnosis and management of HCC in India.
PDF(Pubmed)